Zenas BioPharma, Inc. (ZBIO) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
This phase 3 study, titled “A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Primary Progressive Multiple Sclerosis,” aims to test if Zenas BioPharma’s drug can slow disability in primary progressive MS. It targets a hard to treat group where options are limited, so a positive readout could reshape the company’s future value.
The trial tests orelabrutinib, an oral brain-penetrant drug from the BTK inhibitor class, against a matching placebo. The goal is to reduce disease activity and disability progression while tracking safety over long term use in a broad global patient group.
Patients are randomly assigned in a 2:1 ratio to orelabrutinib or placebo, which lowers bias and tightens the comparison. The study is double blind with patients, doctors, and assessors masked, and the main purpose is to see if the drug works better than placebo in treating primary progressive MS.
The study opened for recruitment after first submission on July 3, 2025, marking the start of formal trial activities for investors tracking pipeline risk. The latest update on May 15, 2026, signals that the sponsor is actively managing the trial, which helps investors gauge operational progress and data timing even though primary and final completion dates are not yet posted.
For Zenas BioPharma, Inc. (ZBIO), steady progress in this phase 3 MS trial can support a higher pipeline value and reduce perceived risk, though delays or safety issues could pressure the stock. Investors should also watch other BTK MS players, such as Sanofi and Roche, since strong or weak data from competitors could shift sentiment for the whole group and influence how the market prices ZBIO’s chances.
The orelabrutinib phase 3 study for primary progressive MS remains active and recruiting, with the latest details and ongoing updates available on the ClinicalTrials portal.
To learn more about ZBIO’s potential, visit the Zenas BioPharma, Inc. drug pipeline page.